Suppr超能文献

星状神经节阻滞缓解广泛性焦虑障碍睡眠障碍的疗效及潜在机制的探索性分析:一项排除共病抑郁的随机对照试验

Efficacy and exploratory analysis of potential mechanisms of stellate ganglion block in alleviating sleep disturbance in generalized anxiety disorder: a randomized controlled trial excluding comorbid depression.

作者信息

Liu Na, Ma Qinying, Zhou Moqing, Yang Lin, Wang Wenyuan, Wang Yanyong

机构信息

Department of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

出版信息

Front Neurol. 2025 May 7;16:1554841. doi: 10.3389/fneur.2025.1554841. eCollection 2025.

Abstract

OBJECTIVE

To investigate the efficacy and mechanisms of stellate ganglion block (SGB) in treating generalized anxiety disorder (GAD) with sleep disturbance, excluding patients with comorbid depression.

METHODS

This double-blind randomized controlled trial (RCT) enrolled 128 patients with GAD (Hamilton Anxiety Scale [HAMA] > 14, Generalized Anxiety Disorder 7-item Scale [GAD-7] ≥ 5) and sleep disturbance (Pittsburgh Sleep Quality Index [PSQI] ≥ 15), randomized to receive SGB ( = 64, 4 ultrasound-guided 1% lidocaine injections) or conventional treatment ( = 64, cognitive behavioral therapy [CBT] + estazolam 1-2 mg/day). Outcomes included anxiety (HAMA), depression (Hamilton Depression Scale [HAMD]), sleep quality (PSQI), polysomnography (PSG), and neurotransmitter levels (norepinephrine [NE], serotonin [5-HT], neuropeptide Y [NPY]).

RESULTS

After 4 weeks, SGB demonstrated higher efficacy (98.4% vs. 89.1%,  = 0.028) and greater reductions in HAMA (9.36 ± 2.34 vs. 11.87 ± 2.71,  < 0.001) and HAMD scores (6.87 ± 2.01 vs. 8.09 ± 2.04,  < 0.001). PSQI improved significantly in the SGB group (5.74 ± 1.64 vs. 8.03 ± 1.86,  < 0.001), with increased total sleep time (TST) (429.76 ± 33.22 vs. 391.13 ± 30.76 min,  < 0.001) and efficiency (90.23 ± 13.29% vs. 86.34 ± 12.84%,  < 0.001). Neurotransmitter analysis showed reduced NE (289.43 ± 51.68 vs. 253.78 ± 57.12 pg./mL,  < 0.05) and increased 5-HT (138.56 ± 19.73 vs. 124.93 ± 18.44 ng/mL,  < 0.05) and NPY (453.21 ± 73.41 vs. 402.34 ± 68.12 pg./mL,  < 0.05). Adverse events were comparable (6.25% vs. 3.13%,  = 0.403).

CONCLUSION

SGB effectively improves GAD symptoms and sleep quality in patients without comorbid depression, potentially via modulation of NE, 5-HT, and NPY pathways. The exclusion of psychiatric comorbidities enhances the specificity of these findings.

摘要

目的

探讨星状神经节阻滞(SGB)治疗伴有睡眠障碍的广泛性焦虑症(GAD)的疗效及机制,排除合并抑郁症的患者。

方法

这项双盲随机对照试验(RCT)纳入了128例GAD患者(汉密尔顿焦虑量表[HAMA]>14,广泛性焦虑症7项量表[GAD-7]≥5)且伴有睡眠障碍(匹兹堡睡眠质量指数[PSQI]≥15),随机分为接受SGB组(n = 64,4次超声引导下注射1%利多卡因)或传统治疗组(n = 64,认知行为疗法[CBT]+艾司唑仑1 - 2mg/天)。观察指标包括焦虑(HAMA)、抑郁(汉密尔顿抑郁量表[HAMD])、睡眠质量(PSQI)、多导睡眠图(PSG)以及神经递质水平(去甲肾上腺素[NE]、血清素[5-HT]、神经肽Y[NPY])。

结果

4周后,SGB显示出更高的疗效(98.4%对89.1%,P = 0.028),HAMA评分(9.36±2.34对11.87±2.71,P<0.001)和HAMD评分(6.87±2.01对8.09±2.04,P<0.001)降低更明显。SGB组PSQI显著改善(5.74±1.64对8.03±1.86,P<0.001),总睡眠时间(TST)增加((429.76±33.22对391.13±30.76分钟,P<0.001),睡眠效率提高(90.23±13.29%对86.34±12.84%,P<0.001)。神经递质分析显示NE降低(289.43±51.68对253.78±57.12pg./mL,P<0.05),5-HT增加(138.56±19.73对124.93±18.44ng/mL,P<0.05),NPY增加(453.21±73.41对402.34±68.12pg./mL,P<0.05)。不良事件发生率相当(6.25%对3.13%,P = 0.403)。

结论

SGB可有效改善无合并抑郁症患者的GAD症状和睡眠质量,可能是通过调节NE、5-HT和NPY通路实现。排除精神共病增强了这些研究结果的特异性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验